Business Description
TScan Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US89854M1018
Description
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3 | |||||
| Equity-to-Asset | 0.66 | |||||
| Debt-to-Equity | 0.39 | |||||
| Debt-to-EBITDA | -0.88 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -0.23 | |||||
| Beneish M-Score | -3.2 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 92.5 | |||||
| 3-Year EBITDA Growth Rate | -5.4 | |||||
| 3-Year EPS without NRI Growth Rate | -7.6 | |||||
| 3-Year FCF Growth Rate | -48 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 64.05 | |||||
| 9-Day RSI | 52.29 | |||||
| 14-Day RSI | 48.52 | |||||
| 6-1 Month Momentum % | -41.93 | |||||
| 12-1 Month Momentum % | -17.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.56 | |||||
| Quick Ratio | 9.56 | |||||
| Cash Ratio | 9.46 | |||||
| Days Sales Outstanding | 1244.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26 | |||||
| Shareholder Yield % | -1.93 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1276.07 | |||||
| Net Margin % | -1188.88 | |||||
| FCF Margin % | -1181.18 | |||||
| ROE % | -60.03 | |||||
| ROA % | -36.44 | |||||
| ROIC % | -107.12 | |||||
| ROC (Joel Greenblatt) % | -156.61 | |||||
| ROCE % | -39.39 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 49.69 | |||||
| PB Ratio | 1.11 | |||||
| Price-to-Tangible-Book | 1.11 | |||||
| EV-to-EBIT | -0.69 | |||||
| EV-to-Forward-EBIT | -0.47 | |||||
| EV-to-EBITDA | -0.72 | |||||
| EV-to-Revenue | 7.88 | |||||
| EV-to-Forward-Revenue | 25.45 | |||||
| EV-to-FCF | -0.67 | |||||
| Price-to-Net-Current-Asset-Value | 1.64 | |||||
| Price-to-Net-Cash | 1.67 | |||||
| Earnings Yield (Greenblatt) % | -144.93 | |||||
| FCF Yield % | -43.44 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TCRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TScan Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 9.362 | ||
| EPS (TTM) ($) | -0.96 | ||
| Beta | 0.78 | ||
| Volatility % | 65.13 | ||
| 14-Day RSI | 48.52 | ||
| 14-Day ATR ($) | 0.347414 | ||
| 20-Day SMA ($) | 4.888 | ||
| 12-1 Month Momentum % | -17.82 | ||
| 52-Week Range ($) | 3.92 - 9.69 | ||
| Shares Outstanding (Mil) | 53.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TScan Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TScan Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
TScan Therapeutics Inc Frequently Asked Questions
What is TScan Therapeutics Inc(TCRX)'s stock price today?
The current price of TCRX is $4.77. The 52 week high of TCRX is $9.69 and 52 week low is $3.92.
When is next earnings date of TScan Therapeutics Inc(TCRX)?
The next earnings date of TScan Therapeutics Inc(TCRX) is 2025-03-06 Est..
Does TScan Therapeutics Inc(TCRX) pay dividends? If so, how much?
TScan Therapeutics Inc(TCRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers